؉ currents (I DR ) in pancreatic ␤-cells are thought to contribute to action potential repolarization and thereby modulate insulin secretion. The voltagegated K ؉ channel, K V 2.1, is expressed in ␤-cells, and the biophysical characteristics of heterologously expressed channels are similar to those of I DR in rodent ␤-cells. A novel peptidyl inhibitor of K V 2.1/K V 2.2 channels, guangxitoxin (GxTX)-1 (half-maximal concentration ϳ1 nmol/l), has been purified, characterized, and used to probe the contribution of these channels to ␤-cell physiology. In mouse ␤-cells, GxTX-1 inhibits 90% of I DR and, as for K V 2.1, shifts the voltage dependence of channel activation to more depolarized potentials, a characteristic of gating-modifier peptides. GxTX-1 broadens the ␤-cell action potential, enhances glucose-stimulated intracellular calcium oscillations, and enhances insulin secretion from mouse pancreatic islets in a glucose-dependent manner. These data point to a mechanism for specific enhancement of glucose-dependent insulin secretion by applying blockers of the ␤-cell I DR , which may provide advantages over currently used therapies for the treatment of type 2 diabetes.
I
nsulin secretion from pancreatic ␤-cells in response to glucose is regulated by ATP-sensitive K ϩ channel (K ATP channel) and by K ATP channel-independent pathways (1). In the K ATP channel-dependent pathway, changes in cellular ATP/ADP levels brought about by the metabolism of glucose cause closure of K ATP channels, which sets the resting membrane potential of these cells. The closure of K ATP channels leads to depolarization of the plasma membrane, opening of voltage-gated calcium channels, and an increase in cytosolic free calcium, [Ca 2ϩ ] i , to trigger insulin secretion (2) . Sulfonylureas, the current first-line treatment in type 2 diabetes, block K ATP channels to induce insulin secretion, but because the action of sulfonylureas is not glucose dependent, patients often exhibit episodes of hypoglycemia (3) .
In addition to K ATP channels, several other types of K ϩ channels are present in ␤-cells, such as large-conductance calcium-activated K ϩ channel (4), a voltage-independent calcium-activated K ϩ channel (5, 6) , and a rapidly inactivating voltage-gated K ϩ channel (7, 8) . The delayed-rectifier K ϩ current (I DR ) is prominent in ␤-cells from several species, including humans (9) , and is thought to contribute to repolarization of action potentials (10) . Inhibition of I DR should broaden action potentials, raise intracellular calcium levels, and enhance insulin secretion in a glucose-dependent manner (8, 11, 12) . For these reasons, the ␤-cell I DR has been considered a potential target for the development of novel agents for treatment of type 2 diabetes (13), although its molecular identity remains to be defined.
Of the K V channel subtypes that have been reported to be expressed in islet tissue, K V 2.1 is prominent in ␤-cells and exhibits biophysical properties similar to the ␤-cell I DR (13) . A K V 2.1 dominant-negative construct reduced ␤-cell I DR and enhanced glucose-stimulated insulin secretion (GSIS) (8) . In addition, hanatoxin (HaTX), a peptidyl K V 2.1 inhibitor, has been reported to enhance GSIS (14) and to induce calcium oscillations in mouse and human islets (15) . Lack of commercial availability of HaTX has hindered further studies on the mechanism of reported effects on GSIS.
To probe the role of I DR in ␤-cells, a novel peptide inhibitor, guangxitoxin (GxTX)-1, was purified to homogeneity and synthetically produced. This peptide is a potent inhibitor of K V 2.1/K V 2.2 channels and inhibits most of I DR in mouse ␤-cells. GxTX-1 broadens the ␤-cell action potential, enhances calcium oscillations, and augments GSIS but has no effect on secretion under low-glucose conditions. These data suggest that K V 2.1 is a component of I DR in ␤-cells and that I DR represents an attractive target for the treatment of type 2 diabetes. presence of test compound was added, and incubation proceeded for additional 10 min. 86 Rb ϩ efflux was quantitated as previously described (21) . Patch-clamp electrophysiology. Membrane currents were recorded at room temperature (23-25°C) using standard dialyzed, whole-cell voltage clamp techniques (22) as described previously (9) . From a holding potential of Ϫ80 mV, currents were activated by step depolarizations to potentials defined in the figures. For perforated-patch current clamp measurement of membrane potential, pipettes were filled with a solution containing (in mmol/l) 76 K 2 SO 4 , 10 KCl, 10 NaCl, 1 MgCl 2 , and 5 HEPES, pH adjusted to 7.2, with KOH and backfilled with this solution supplemented with 0.24 mg/ml amphotericin B. The external solution was (in mmol/l) 140 NaCl, 3.6 KCl, 2 NaHCO 3 , 0.5 NaH 2 PO 4 , 2.6 CaCl 2 , 0.5 MgSO 4 , and 5 HEPES, pH 7.4, with NaOH and supplemented with 0 -15 mmol/l glucose as indicated. BSA (0.1% wt:vol) was added to GxTX-1 solutions. Xenopus oocyte electrophysiology. Xenopus laevis oocytes were prepared and injected with RNA encoding hK V 2.1, and currents were recorded using two-electrode voltage clamp as described previously (21, 23) . IonWorks 384-well automated electrophysiology. K V currents were recorded using the IonWorks HT system (Molecular Devices, Sunnyvale, CA) as described previously (21, 24) . Currents were measured before and 10 min after the addition of GxTX-1E in D-PBS containing 0.03% BSA. Peak currents at 0 mV (hK V 2.1) or ϩ20 mV (hK V 2.2 and hK V 4.3) were analyzed as described below. Analysis of electrophysiological data. The dose-dependence of tetraethylammonium inhibition of currents was determined from fits of the Hill equation, as described (9) . The dose dependence of GxTX-1E inhibition was described by a single-site or a four-equivalent-site model with the equation 0 ϭ (1 -p) n , where 0 is the probability of the channel having zero GxTX-1E molecules bound, p ϭ [GxTX-1E]/([GxTX-1E] ϩ K D ), and n ϭ 1 or 4, respectively (25) . Fura-2 imaging. Dissociated mouse islet cells on glass coverslips were loaded with fura-2 AM (2 mol/l) and imaged with a Nikon TE300 inverted microscope equipped with a Hamamatsu Orca-ER digital camera and a Lambda DG4 filter changer. Fura-2 was excited at 340 and 380 nm, fluorescence emission at 510 Ϯ 20 nm was imaged every 10 s, and the average fluorescence intensity ratio (R) in a cell (F 340 /F 380 ) was measured over time. To quantify changes in R, area under the curve was measured for 15 min before and 15 min after the addition of GxTX-1E or vehicle and percentage change calculated. Islet isolation. Pancreatic islets of Langerhans were isolated from the pancreata of 8-to 14-week-old C57/B6 mice (Charles River, Wilmington, MA) by collagenase digestion and discontinuous Ficoll gradient separation, a modification of the original method of Lacy and Kostianovsky (26) . The islets were cultured overnight in RPMI-1640 medium (11 mmol/l glucose) before experimental treatment. Measurement of GSIS. GSIS was determined either by static incubation or perifusion of islets in Krebs-Ringer bicarbonate (KRB) medium at 37°C as described (27) . For static GSIS assays, incubation was performed with round-bottomed 96-well plates (1 islet/well with 200 l KRB medium). K ATP channel-independent GSIS was measured by a modified static assay where, following a 30-min preincubation in unmodified KRB medium, islets were incubated for 60 min in KRB medium with 30 mmol/l KCl, 250 mol/l diazoxide, 2 or 16 mmol/l glucose, and test agents. For islet perifusion, batches of 25 islets each were perifused in parallel microchambers (Biovail, Minneapolis, MN) with oxygenated KRB medium with 2 or 16 mmol/l glucose at a rate of 0.8 ml/min, and the fractions of the perfusate were collected once per minute for insulin measurement. For perfusion of dispersed islet cells, ϳ300 freshly hand-picked islets were washed twice with Ca 2ϩ /Mg 2ϩ -free PBS and incubated in 300 l enzyme-free cell dissociation buffer (Cellstripper; Mediatech, Herndon, VA) at room temperature for 3 min with occasional agitation and further dispersed by gentle trituration. Dispersed cells were rinsed in islet culture medium, and aliquots (50 l) of the cell suspension were transferred to each of three parallel microchambers for perifusion or were used for the measurement of total insulin content. The perifusion procedure for the dispersed cells was the same as for intact islets described above, except that 50 mol/l of Ro-20-1724 (a phosphodiesterase inhibitor) was added to the KRB medium throughout. Insulin concentration in aliquots of the incubation or perifusion buffers was measured by the ultrasensitive rat insulin ELISA kit from ALPCO Diagnostics (Windham, NH).
Statistical analysis.
Experimental values are given as means Ϯ SE. Singlefactor ANOVA was used to compare mean values between groups in the GSIS experiments.
RESULTS
To assess the contribution of K V 2.1 to the ␤-cell I DR , 85 venoms were screened in a functional 86 Rb ϩ efflux assay using a stable CHO.K V 2.1 cell line. Venom from the tarantula, Plesiophrictus guangxiensis sp. nov., was found to display the highest inhibitory potency and was fractionated by HPLC. The most active purified fraction, GxTX-1, was sequenced and found to consist of two variants, 65% GxTX-1E and 35% GxTX-1D, that only differ at the NH 2 -terminal residue, glutamate or aspartate, respectively (Table 1). A small inactive peak that elutes separately from GxTX-1 is present in the native purified sample (Fig. 1A) . Such behavior has also been observed in the separation of HaTX (28) . A second less-active fraction, GxTX-2, was also sequenced. GxTX-2 is related to the K V 2.1 gating-modifier peptides, HaTX, ScTx1, and SGTx (28 -30) . GxTX-1 exhibits very little sequence identity with any of these peptides but is related to the gating-modifier peptides, Jingzhaotoxin-III (31), GsMTx-4 (32), and VSTX1 (33), peptidyl tarantula venom inhibitors of sodium, nonselective stretch, and the bacterial K ϩ channel K V AP, respectively (Table 1) .
To confirm the identity of the purified peptides and because of their low abundance in the native venom, both GxTX-1E and GxTX-1D were produced by solid-phase synthesis. Folded GxTX-1E coelutes with native peptide in reverse-phase HPLC (Fig. 1 ). GxTX-1D shows identical chromatographic behavior (not shown). In the 86 Rb ϩ efflux assay, GxTX-1E is a slightly more potent K V 2.1 inhibitor than the purified native mixture and GxTX-1D (half-maximal concentration [IC 50 ] values of 0.71, 1.5, and 1.8 nmol/l, respectively; n ϭ 2) (Fig. 1B) , suggesting that synthetic GxTX-1 has similar characteristics to native peptide. Because of the advantage of being able to produce large quantities of biologically active peptide, synthetic GxTX-1E was further characterized and used to probe the role of I DR in ␤-cells. GxTX-1E is a gating-modifier peptide. Inhibition of K V 2.1 by GxTX-1E was characterized by whole-cell voltage-clamp electrophysiology. GxTX-1E (43 nmol/l) inhibited the current in CHO.hK V 2.1 cells at both ϩ20 mV and ϩ80 mV ( Fig. 2A-C) . At ϩ20 mV, 43 nmol/l GxTX-1E inhibited CHO.hK V 2.1 current 98 Ϯ 1% (n ϭ 5). The current-voltage relation shows that GxTX-1E shifts the voltage-dependence of hK V 2.1 channel activation, a hallmark feature of gating-modifier peptides ( Works automated electrophysiology, GxTX-1E had no significant effect on K V 1.2, K V 1.3, K V 1.5, or K V 3.2 channels. However, as observed with HaTX (28) and ScTx1 (29), GxTX-1E inhibited K V 4.3 channels with IC 50 s of 24 ( Fig.  2F ) and 54 nmol/l in two experiments. Thus, GxTX-1E is at least eightfold weaker on K V 4.3 as compared with K V 2 channels. Because K V 4 channels produce a rapidly inactivating A-type current, they are not expected to be related to the slowly inactivating I DR . In other assays, GxTX-1E had no significant activity against the high-conductance, calcium-activated K ϩ channel, the calcium channels Ca v 1.2 and Ca v 2.2, or the sodium channels Na v 1.5, Na v 1.7, and Na v 1.8. Therefore, GxTX-1E is an appropriate probe for studying the contribution of K V 2 channels to the ␤-cell I DR . GxTX-1E inhibits the delayed rectifier of mouse ␤-cells. Similar to hK V 2.1 channels, I DR of mouse ␤-cells inactivates slowly and is inhibited by GxTX-1E (Fig. 3A-C) . When measured at ϩ20 mV, 43 nmol/l GxTX-1E inhibited I DR of mouse ␤-cells by 89 Ϯ 3% (n ϭ 11). As seen with hK V 2.1, the inhibition of I DR by GxTX-1E is less prominent at more positive voltages (Fig. 3D) . However, at greater depolarizations, significant differences were seen between the interaction of GxTX-1E with the ␤-cell current and hK V 2.1. At ϩ80 mV, the fraction of mouse ␤-cell I DR blocked by 43 nmol/l GxTX-1E was 57 Ϯ 3% (n ϭ 11) compared with 93 Ϯ 2% for hK V 2.1 channels (Fig. 3E) . In addition, the potency of the nonselective K ϩ channel blocker TEA is greater on the ␤-cell I DR (IC 50 2.2 mmol/l) than on hK V 2.1 expressed in Xenopus oocytes (IC 50 8.2 mmol) (Fig. 3F) . The potency of TEA block of hK V 2.1 channels was confirmed with CHO.K V 2.1 cells (IC 50 9.3 mmol/l; not shown). Mouse ␤-cell action potentials are broadened by application of GxTX-1E. Consistent with the idea that the ␤-cell I DR is involved in action potential repolarization (10), GxTX-1E broadened glucose-induced action potentials in mouse ␤-cells (Fig. 4A-C) . In contrast to previous reports where a nonselective K ϩ channel inhibitor, TEA, was used (34), the selectivity of GxTX-1E confirms that action potential broadening in the presence of high glucose occurs through inhibition of I DR alone. To measure the effect of GxTX-1E on action potential repolarization more systematically, we evoked action potentials by depolarizing current injection (Fig. 4D) . GxTX-1E slowed the rate (dV/dt) of action potential repolarization by 53 Ϯ 7% (n ϭ 4) and increased action potential duration by 30 Ϯ 6% (n ϭ 4; measured at half height). GxTX-1E had no effect on the resting membrane potential of ␤-cells in low glucose (not shown), unlike inhibitors of K ATP channels. inducing [Ca 2ϩ ] i oscillations that were stable for nearly 1 h (Fig. 5A and B) . For example, when the area under the curve is measured from 15 to 30 min and from 30 to 45 min for the cells in Fig. 5A and B, [Ca 2ϩ ] i rose only 3 and 10%, respectively, between these time periods. On average, [Ca 2ϩ ] i increased 9 Ϯ 4% (n ϭ 27) over this time. We then asked if inhibition of I DR by GxTX-1E would enhance [Ca 2ϩ ] i . GxTX-1E (43 nmol/l) was added to the bath after ϳ15 min of stable [Ca 2ϩ ] i oscillations. Figure 5C -F shows examples of individual cells from a single experiment and demonstrates the types of responses seen after exposure to GxTX-1E. In some cells, the oscillations became broader (Fig. 5C ), while in others the frequency increased (Fig. 5D) . In some cells, GxTX-1E restored oscillations that had stopped (Fig. 5E) , while in others GxTX-1E had only a modest effect (Fig. 5F ). On average, GxTX-1E produced a 38 Ϯ 5% (n ϭ 61) increase in [Ca 2ϩ ] i relative to the period before GxTX-1E addition. Importantly, GxTX-1E had no effect on [Ca 2ϩ ] i when applied in low (3 mmol/l) glucose (not shown), and the enhanced [Ca 2ϩ ] i oscillations produced by GxTX-1E in 8 mmol/l glucose were rapidly terminated upon lowering of glucose (Fig.  5C-F) . GSIS is enhanced by GxTX-1E. The findings that GxTX-1E is an effective inhibitor of the ␤-cell I DR and enhances glucose-dependent Ca 2ϩ oscillations suggest that it should augment GSIS. As expected, insulin secretion at 16 mmol/l glucose was enhanced 3.5-fold by 2 mol/l GxTX-1E when tested in a static assay ( Fig. 6A ; P Ͻ 0.001). TEA (10 mmol/l) enhanced GSIS twofold ( Fig. 6A ; P Ͻ 0.01). These effects on insulin secretion were glucose dependent, since neither GxTX-1E nor TEA had an effect at 2 mmol/l glucose. As a positive control, 10 nmol/l GLP-1 enhanced GSIS by fivefold (P Ͻ 0.001). The enhancement of GSIS by GxTX-1E was also observed in perifusion studies of mouse islets. The addition of GxTX (1 mol/l) to the perifusate with 16 mmol/l glucose doubled the rate of insulin secretion (average insulin concentration 2.1 Ϯ 0.5 ng/ml) compared with perifusion in glucose alone (1.1 Ϯ 0.2 ng/ml) (Fig. 6B) .
Addition of TEA after a 20-min wash of GxTX resulted in additional enhancement over the GxTX-enhanced signal (Fig. 6B, P ϭ 0.060) . Since recovery from GxTX-1E inhibition of hK V 2.1 is slow (off time constant [ off ] ϳ28 min; not shown), the effect of TEA in these experiments may be due to both TEA and the residual effects of GxTX-1E. The additional enhancement produced by TEA may also arise from the action of TEA on other channels besides K V channels.
In separate static assays of intact islets, GxTX-1E was found to have an EC 50 of 400 nmol/l for the enhancement of GSIS (n ϭ 2, not shown). However, in dispersed islet cells, GxTX-1E was more potent (Fig. 6C) than it is in intact islets. Both 50 nmol/l and 1 mol/l GxTX-1E exhibited a significant enhancement over 16 mmol/l glucose alone (average [10 -20 min] respective % insulin content/ min 0.54 Ϯ 0.07, 0.48 Ϯ 0.05, and 0.31 Ϯ 0.04, P Ͻ 0.05), and were not significantly different from each other. The enhancement of GSIS by GxTX-1E was not due to effects on the K ATP channel-independent pathway, as shown in Fig. 6D . In the presence of elevated KCl (30 mmol/l) to depolarize the plasma membrane and diazoxide (250 mol/l) to maintain K ATP channels in the open state, insulin secretion was significantly higher at 16 than at 2 mmol/l glucose (10.2 vs. 6.1 ng ⅐ islet Ϫ1 ⅐ h Ϫ1 , n ϭ 4, P ϭ 0.01), but neither 1 mol/l GxTX-1E nor 5 mmol/l TEA caused additional insulin release. Note that in the controls, GxTX-1E and TEA repeated their enhancement of insulin secretion over that at 16 mmol/l glucose (P Ͻ 0.05). Taken together, these data point to a mechanism for specific enhancement of insulin secretion at elevated glucose levels by blocking the ␤-cell I DR .
DISCUSSION
In this study, we report the identification, purification, primary sequence determination, synthesis, and use of GxTX-1, a potent inhibitor of the ␤-cell I DR . GxTX-1 broadens ␤-cell action potentials, increases calcium oscillations, and enhances GSIS. GxTX-1 inhibits 90% of the ␤-cell I DR , making it a suitable probe for the physiological role of the I DR . GxTX-1 broadens the glucose-induced action potential but has no effect on the resting potential in low glucose. Similarly, GxTX-1 augments glucose-dependent calcium oscillations without affecting resting [Ca 2ϩ ] i . Further, the stimulation of insulin secretion by GxTX-1 is strictly glucose dependent, as expected, since I DR is only active at membrane potentials above Ϫ20 mV, a depolarization level only seen in elevated glucose. This property, coupled with slow opening kinetics (Fig. 3A) , makes the I DR ideal for contributing to the repolarization phase of the ␤-cell action potential. The observation that GxTX-1 has no effect on the K ATP channel-independent pathways suggests that the observed effects of GxTX-1 on insulin secretion are limited to inhibition of I DR .
The concentration (43 nmol/l) at which GxTX-1 broadens action potentials and enhances calcium oscillations and the concentration (50 nmol/l) at which GxTX-1 enhances insulin secretion from dispersed islet cells are consistent with inhibition of the mouse ␤-cell I DR . However, higher concentrations (EC 50 ϳ400 nmol/l) of GxTX-1 were required to enhance GSIS in intact islets, suggesting a more difficult access of the peptide to the core of the islets as compared with dispersed single ␤-cells. A similar scenario has been suggested to explain the effects of HaTX on calcium oscillations in whole islets (15) . Nonetheless, the effects of GxTX-1 taken together are consistent with the hypothesis that GxTX-1 enhances insulin secretion from mouse islets through inhibition of the ␤-cell I DR . Identity of the delayed-rectifier channels in mouse ␤-cells. Selectivity studies with GxTX-1 suggest that the major, GxTX-1-sensitive component of the ␤-cell I DR contains K V 2 subunits. The only other channel we identified that is blocked by GxTX-1 is K V 4.3, which is not likely to contribute significantly to the ␤-cell I DR , since it is neither expressed in mouse ␤-cells (13) nor found in human islets by PCR (35) . In addition, K V 4 channels normally produce a rapidly inactivating current, distinct from the slowly inactivating I DR of ␤-cells.
Of the two known K V 2 family members, K V 2.1 is the best candidate to encode I DR . K V 2.1 is expressed at high levels in islets from various species (8, 12) , and immunohistochemical analysis indicates that expression of K V 2.1 in primate islets is restricted to ␤-cells (35) . The other member of the K V 2 family, K V 2.2, appears to be specifically located in ␦-cells of primate islets (35) and is not found in rat islets (8) .
Although block of the ␤-cell I DR suggests the presence of K V 2.1, clear differences between the mouse ␤-cell I DR and hK V 2.1 were observed. The GxTX-1-induced shift in voltage-dependent channel opening was greater for hK V 2.1 than for mouse ␤-cell I DR , and mouse ␤-cell I DR is more sensitive to TEA than hK V 2.1 (Fig. 3F) . These pharmacological differences are not likely due to species differences. The sequences of mouse and human K V 2.1 are nearly identical, and sequence identity is 100% in the regions where gating modifiers and TEA are thought to bind. Indeed, the I DR of human ␤-cells is also more sensitive to TEA (IC 50 0.54 mmol/l) (9) than hK V 2.1. The pharmacological differences between native and heterologously expressed channels may be due to posttranslational modification, association of unknown accessory subunits, or heterotetramerization of ␣ subunits. Gating modifier peptides, unlike pore blockers, bind to the channel with a stoichiometry of 4:1, and the number of inhibitor molecules bound determines the amplitude of the shift in channel gating (25) . Coassembly of K V 2.1 subunits with GxTX-1-insensitive, TEA-sensitive subunits, might result in a pharmacological profile similar to that of the I DR of ␤-cells.
In this study, we have shown that GxTX-1 is a novel and suitable tool to probe the role of the ␤-cell I DR in insulin secretion and to investigate the molecular composition of the ␤-cell I DR . The glucose dependence of the effects of GxTX-1 on both [Ca 2ϩ ] i oscillations and insulin release predict that a blocker of I DR , unlike K ATP channel blockers, should not induce hypoglycemia and may represent an improved approach for the treatment of type 2 diabetes. Lastly, the availability of biologically active synthetic GxTX-1 should facilitate studies of the mechanisms that control insulin secretion.
